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► BACKGROUND 
The National Institute for Health and Care Excellence (NICE) has previously 
recommended the use of peginterferon alfa (peg α) and ribavirin combination 
therapy in adults with chronic hepatitis C virus (HCV) in the UK. Optimal therapy 
for children and young people is less clear but it has been suggested that they 
should be treated using the guidelines as for adults to minimise the chance of 
liver damage and social stigma some children experience.  
►  OBJECTIVE 
To assess the cost-effectiveness of peginterferon α-2a and peginterferon α-2b in 
combination with ribavirin compared to best supportive care (BSC), for the 
treatment of HCV in children and young people aged 3 to 17 years.  
►  METHODS 
A Markov state-transition economic model of chronic HCV in children and young 
people was developed that extrapolated the impact of sustained virological 
response (SVR) on life expectancy, quality-adjusted life expectancy and lifetime 
costs (Figure 1). The model was adapted from one previously developed for 
adults. Systematic reviews were conducted of the clinical effectiveness of the 
treatments, and the health related quality of life for patients with hepatitis C. The 
perspective of the analysis was that of the UK NHS and Personal Social Services 
and costs and benefits were discounted at 3.5%. Uncertainty in the model was 
explored through probabilistic and deterministic sensitivity analyses. 
 
►  RESULTS 
Seven studies were identified for clinical effectiveness of peginterferon in children. 
The studies were single arm, uncontrolled cohort studies and were relatively small 
and of generally poor quality. The estimates of SVR were similar for peginterferon 
α-2a and peginterferon α-2b (Table 1), whilst the SVR for no treatment was 
assumed to be zero.  
From this model, peginterferon alfa (α-2a or α-2b) in combination with ribavirin was 
more effective and cheaper than BSC (Table 2). Sensitivity analyses suggest that 
the results were generally robust to all changes to the structural assumptions and 
input parameters. The model results were most sensitive to changes to the 
discount rate, time horizon, SVR and baseline fibrosis of the cohort.  
►  CONCLUSIONS & DISCUSSION 
Treatment of children and young people with peginterferon alfa (α-2a or α-2b) and 
ribavirin may be a clinically effective therapy. Peginterferon alfa (α-2a or α-2b) in 
combination with ribavirin is cost-effective compared with BSC. However, the 
reliability of the available evidence is questionable given the single cohort study 
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Figure 1: State transition diagram for hepatitis C economic model 
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BSC £29,245 20.53       
PEG α-2a + Ribavirin £19,055 22.25 -£10,190 1.72 dominatesa 
PEG α-2b + Ribavirin £20,371 22.19 -£8,874 1.66 dominatesa 
QALY – quality adjusted life year; ICER – incremental cost effectiveness ratio 
a i.e. peginterferon alfa is cheaper and more effective than BSC 
Table 2: SHTAC discounted base case results versus best supportive care 
Treatment SVR, % 95% CI Source 
PEG α-2a + 
Ribavirin 
60.00 51.23, 68.76 Schwarz, 2011; Sokal, 2010 
PEG α-2b + 
Ribavirin 
58.37 51.69, 65.05 
Al Ali, 2010;Pawlowska, 2010;Wirth, 2010; 
Ghaffar, 2009; Jara, 2007 
Table 1: Effectiveness input parameters used in economic model 
